Pfizer Inc.

COVID-19 booster shot used for children 5-11 strengthens immune response: Pfizer

BioNTech’s trial for Omicron-based COVID-19 vaccines expanding

U.S. FDA authorizes a fourth Pfizer, Moderna COVID-19 booster shot for people aged 50 and older

U.K. study to test Pfizer’s COVID-19 pill in hospitalized patients

Pharmacists say they should be playing a bigger role in providing access to COVID-19 medication

Pfizer to sell up to four million courses of COVID-19 pills to UNICEF this year

Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine

Expert panel recommends children get Pfizer COVID-19 vaccine, calls Moderna suitable alternative

Pfizer to maintain drug supply to Russia, but will stop new clinical trials in country

Pfizer begins mid-to-late-stage study of COVID-19 pill for high-risk children aged 6-17

Delay ahead for Pfizer’s COVID-19 vaccine for kids under 5

Pfizer’s forecast for 2022 sales of its COVID-19 vaccine, antiviral pill falls short of estimates

FDA urges Pfizer to apply for under-5 COVID-19 vaccine authorization

The promises and limitations of the new COVID-19 pill

Ontario releases guidelines for Paxlovid COVID-19 treatment eligibility

A COVID-19 vaccine mandate in schools could harm many low-income kids

Johnson & Johnson expects COVID-19 vaccine sales to jump as much as 46% in 2022

Annual COVID-19 vaccine preferable to more frequent booster shots, Pfizer CEO says

Vaccines are a tool, not a silver bullet. If we’d allowed more scientific debate, we would have realized this earlier